Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Syros Pharmaceuticals Inc SYRS

Healthcare Biotechnology
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARa), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in... see more

Recent & Breaking News (NDAQ:SYRS)

Syros to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

Business Wire November 5, 2019

Syros Presents New Preclinical Data on SY-5609, Its Highly Selective Oral CDK7 Inhibitor, at AACR-NCI-EORTC International Conference

Business Wire October 29, 2019

Syros Announces New Data from Phase 2 Trial of SY-1425 in Combination with Azacitidine Demonstrating High Response Rates, Rapid Onset of Action and Favorable Tolerability Profile in RARA-Positive Newly Diagnosed Unfit AML Patients

Business Wire October 24, 2019

Syros Announces Update on Selective CDK7 Inhibitor Portfolio

Business Wire October 17, 2019

Syros to Present at 2019 Wedbush PacGrow Healthcare Conference

Business Wire August 6, 2019

Syros Reports Second Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Business Wire August 1, 2019

Syros to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019

Business Wire July 25, 2019

Syros Announces Appointment of Alice T. Shaw to its Board of Directors

Business Wire June 12, 2019

Syros to Present at JMP Securities Life Sciences Conference

Business Wire June 12, 2019

New Publication in Cancer Research Highlights Discovery of SY-1365, a First-in-Class Selective CDK7 Inhibitor, and its Promise as a Potentially Transformative Targeted Approach for Difficult-to-Treat Cancers

Business Wire May 7, 2019

Syros Reports First Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Business Wire May 1, 2019

Syros to Report First Quarter 2019 Financial Results on Wednesday, May 1, 2019

Business Wire April 24, 2019

Syros to Host Key Opinion Leader Symposium on CDK7 Inhibition on April 24, 2019

Business Wire April 17, 2019

Syros Announces Closing of Concurrent Public Offerings

Business Wire April 9, 2019

Syros Announces Pricing of $70 Million Concurrent Public Offerings

Business Wire April 5, 2019

Syros Announces Proposed Concurrent Public Offerings of Common Stock with Warrants to Purchase Common Stock and Preferred Stock with Warrants to Purchase Common Stock

Business Wire April 4, 2019

Syros Presents New Preclinical Data on SY-1365 and SY-5609 at AACR Annual Meeting

Business Wire April 2, 2019

Syros Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Multiple Upcoming Clinical Milestones for Its First-in-Class Programs

Business Wire March 7, 2019

Syros to Participate in Upcoming Investor Conferences in March

Business Wire March 6, 2019

Syros to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 7, 2019

Business Wire February 28, 2019